Article

Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

Catalan Institute of Oncology, Girona (ICO-Girona), Dr. Josep Trueta University Hospital, Ctra. França s/n, 17007, Girona, Catalonia, Spain.
Breast Cancer Research and Treatment (Impact Factor: 4.2). 05/2010; 126(2):355-64. DOI: 10.1007/s10549-010-0924-x
Source: PubMed

ABSTRACT We here demonstrate that the anti-diabetic drug metformin interacts synergistically with the anti-HER2 monoclonal antibody trastuzumab (Tzb; Herceptin™) to eliminate stem/progenitor cell populations in HER2-gene-amplified breast carcinoma cells. When using the mammosphere culture technique, graded concentrations of single-agent metformin (range 50-1,000 μmol/l) were found to dose-dependently reduce the number of mammospheres formed by SKBR3 (a Tzb-naïve model), SKBR3 TzbR (a model of acquired auto-resistance to Tzb) and JIMT-1 (a model of refractoriness to Tzb and other HER2-targeted therapies ab initio) HER2-overexpressing breast cancer cells. Single-agent Tzb likewise reduced mammosphere-forming efficiency (MSFE) in Tzb-naïve SKBR3 cells, but it failed to significantly decrease MSFE in Tzb-resistant SKBR3 TzbR and JIMT-1 cells. Of note, CD44-overexpressing Tzb-refractory SKBR3 TzbR and JIMT-1 cells retained an exquisite sensitivity to single-agent metformin. Concurrent combination of metformin with Tzb synergistically reduced MSFE as well as the size of mammospheres in Tzb-refractory SKBR3 TzbR and JIMT-1 cells. Flow cytometry analyses confirmed that metformin and Tzb functioned synergistically to down-regulate the percentage of Tzb-refractory JIMT-1 cells displaying the CD44(pos)/CD24(neg/low) stem/progenitor immunophenotype. Given that MSFE and mammosphere size are indicators of stem self-renewal and progenitor cell proliferation, respectively, our current findings reveal for the first time that: (a) Tzb refractoriness in HER2 overexpressors can be explained in terms of Tzb-resistant/CD44-overexpressing/tumor-initiating stem cells; (b) metformin synergistically interacts with Tzb to suppress self-renewal and proliferation of cancer stem/progenitor cells in HER2-positive carcinomas.

Download full-text

Full-text

Available from: Alejandro Vazquez-Martin, Aug 25, 2015
1 Follower
 · 
125 Views
  • Source
    • "various cancer stem cells (Janzer et al. 2014; Honjo et al. 2014; Lonardo et al. 2013; Shank et al. 2012; Song et al. 2012; Vazquez-Martin et al. 2011; Hirsch et al. 2009; Viale et al. 2014). Indeed, a number of clinical trials of metformin are ongoing as therapy for a variety of cancers (Pollak 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: 5′-AMP-activated protein kinase (AMPK) plays a pivotal role in maintaining energy and redox homeostasis under various metabolic stress conditions. Metabolic adaptation, which can be triggered by the activation of AMPK during metabolic stress, is the critical process for cell survival through the maintenance of ATP and NADPH levels. The importance of such regulation of fundamental process poses the AMPK signaling pathway in one of the most attractive therapeutic targets in many pathologies such as diabetes and cancer. In cancer, however, accumulating data suggest that the role of AMPK would not be simply defined as anti- or pro-tumorigenic, but it seems to have two faces like a double-edged sword. Importantly, recent studies showed that the anti-tumorigenic effects of many ‘indirect’ AMPK activators such as anti-diabetic biguanides are not dependent on AMPK; rather the activation of AMPK induces the resistance to their cytotoxic effects, emphasizing the pro-tumorigenic effect of AMPK. In this review, we summarize and discuss recent findings suggesting the two faces of AMPK in cancer, and discuss how we can exploit this unique feature of AMPK for novel therapeutic intervention.
    Archives of Pharmacal Research 01/2015; 38(3). DOI:10.1007/s12272-015-0549-z · 1.75 Impact Factor
  • Source
    • "Moreover, the ionophore antibiotic salinomycin seems to have even extended capabilities of eliminating cancer, because this compound has been demonstrated to effectively target regular cancer cells [16] [138] [139] [140], highly multidrug and apoptosis resistant cancer cells [16] [138] [141], and CSCs [16] [116] [117] [141] [142] [143] [144] [145] [146]. Finally, recent data obtained in vitro and in xenograft mice bearing human cancers indicate that CSC targeting agents are most effective in eradicating CSCs and their progeny when these agents are combined with conventional cytostatic drugs and/or novel tumor-targeted drugs [90] [116] [117] [131] [141] [143] [147] [148] [149] [150] [151] [152], envisioning the use of complex combination therapies for the future treatment of cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer stem cells (CSCs) are a subpopulation of tumor cells that possess self-renewal and tumor initiation capacity and the ability to give rise to the heterogenous lineages of cancer cells that comprise the tumor. CSCs possess numerous intrinsic mechanisms of resistance to chemotherapeutic drugs, novel tumor-targeted drugs and radiation therapy, allowing them to survive current cancer therapies and to initiate tumor recurrence and metastasis. Recently, different pathways that confer resistance and survival of CSCs, but also compounds and drugs that selectively target some of these pathways in CSCs have been identified. Such compounds and drugs include antibiotics like salinomycin, phytochemicals such as parthenolide, cyclopamine, EGCG, resveratrol, curcumin, sulforaphane and oxymatrine, the small molecule inhibitors vismodegib and repertaxin, monoclonal antibodies and antibody constructs raised against cell surface proteins expressed by CSCs, and, surprisingly, some classical drugs such as metformin, tranilast and thioridazine. These agents exhibit significant anti-CSC activity, alone or in combination with cytostatic drugs or tumor-targeted drugs, as recently shown in vitro and in human xenograft mice. Since current cancer therapies fail to eliminate CSCs, leading to cancer recurrence and progression, selective targeting of CSCs with compounds and drugs introduced herein may represent a novel therapeutic strategy to eradicate cancer.
    The Journal of cancer research 01/2013; 2.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in cancer stem cell (CSC) research and the role of miroRNAs (miRNAs) provided renewed interest, as supported by some convincing data showing that deregulation of miRNAs are important molecular events in the maintenance of CSC niche, which contribute to therapeutic resistance, resulting in treatment failure. Therefore, we are succinctly providing state-of-the-art knowledge on miRNAs that are associated with CSCs in this article, and it is quite clear that CSCs and miRNAs are implicated in therapeutic resistance, suggesting that novel approaches must be devised to eliminate CSCs or drug resistant cells focusing on overcoming therapeutic resistance. This indeed could be achieved by targeted strategies either to re-express the lost miRNAs or inactivate over-expressed miRNAs in cancers in general and CSCs in particular. We sincerely hope that this article would be educational to attract innovative research in the field so that we can find specific novel approaches to eradicate cancer by overcoming therapeutic resistance by targeting miRNAs, which will be useful to eliminate tumor recurrence and metastasis.
    01/2011; 01(S1). DOI:10.4172/2157-2518.S1-005
Show more